Cancer

PRIVACY ALERT: California Cancer Associates for Research and Excellence (cCARE) Under Investigation for Data Breach of Patient Records

SAN FRANCISCO, July 8, 2025 /PRNewswire/ -- Schubert Jonckheer & Kolbe LLP is investigating a data breach that led to unauthorized…

6 months ago

Caris Life Sciences Announces New Study Demonstrating the Power and Clinical Utility of its Caris Assure® Blood-Based Assay for Multi-Cancer Early Detection, Minimal Residual Disease and Therapy Selection

Scientific Reports study validates the first multifunctional, AI-enabled blood-based assay to offer diagnostic, prognostic and predictive utility in a single…

6 months ago

Predictive Oncology Announces $10M Share Purchase Agreement in Partnership with Yorkville Advisors to Advance AI-Driven Drug Discovery and Repurposing

PITTSBURGH, July 08, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery, announced today…

6 months ago

Calidi Biotherapeutics Inc. (NYSE American: CLDI) Developing Precision Genetic Medicine Platform for Cancer Treatment

NEW YORK, July 08, 2025 (GLOBE NEWSWIRE) -- via InvestorWire — Calidi Biotherapeutics Inc. (NYSE American: CLDI) today announces its…

6 months ago

iCAD Announces Proxy Advisory Firms ISS and Glass Lewis Recommend Stockholders Vote “FOR” Proposed Acquisition by RadNet, Inc.

NASHUA, N.H., July 08, 2025 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) (“iCAD” or the “Company”), a global leader in…

6 months ago

Nuvectis Pharma Announces Successful Completion of a Drug-Drug Interaction Study in Healthy Volunteers Supporting NXP900’s Potential as a Combination Partner with Leading Therapies

Drug-drug interaction (“DDI”) clinical studies help identify the potential for side effects, or in some cases, reduced therapeutic efficacy, that…

6 months ago

BriaCell Phase 2 Survival Achievement: 52% of Patients Surpass One-Year Milestone in Metastatic Breast Cancer

52% of BriaCell’s most-recent 25-patient cohort* have surpassed the one-year survival milestone, exceeding current standard of care in similar patients11…

6 months ago

Plus Therapeutics Announces Initial Patients Successfully Treated in ReSPECT-LM Dose Optimization Trial for REYOBIQ™ in Leptomeningeal Metastases

Substantial clinical need expected to facilitate rapid overall trial enrollmentHOUSTON, July 08, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq:…

6 months ago

Crescent Biopharma Appoints Jan Pinkas, Ph.D., as Chief Scientific Officer

Seasoned Leader Brings Deep Experience in Oncology Drug Development as Company Advances Portfolio of Next Generation Therapeutics for Solid Tumors…

6 months ago

Adagene and ConjugateBio Partner to Develop Novel Antibody Drug Conjugate

Adagene to provide proprietary antibody to ConjugateBio for development as novel bispecific ADCs SAN DIEGO and SUZHOU, China and PRINCETON,…

6 months ago